The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib.
 
Severine Guiu Lahaye
No Relationships to Disclose
 
Judith Balmana Gelpi
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - AstraZeneca (Inst)
Patents, Royalties, Other Intellectual Property - European patent request submitted (EP17382884.9) not related to this work
Travel, Accommodations, Expenses - AstraZeneca; Pfizer
 
Ludovic Gauthier
No Relationships to Disclose
 
Frédéric Bigot
Leadership - AstraZeneca/MedImmune; BMSi
Honoraria - AstraZeneca/MedImmune; BMSi; MSD; Roche
Travel, Accommodations, Expenses - Lilly
 
Anthony Goncalves
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst)
 
Jean-Sebastien Frenel
Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology; Daiichi Sankyo Europe GmbH; Gilead Sciences; GlaxoSmithKline; Lilly; Novartis; Novocure; Pfizer; Pierre Fabre; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Europe GmbH; Gilead Sciences; Lilly; Novartis; Pfizer; Roche; Seagen
 
Thomas Bachelot
Consulting or Advisory Role - AstraZeneca; MSD Oncology; Novartis; Pfizer; Roche; Seagen
Research Funding - AstraZeneca (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; pfizer; Roche
 
Florence Dalenc
No Relationships to Disclose
 
Audrey Mailliez
Consulting or Advisory Role - DAICHII SANKYO; PFIZER; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Pierre Fabre
 
Camille Chakiba
No Relationships to Disclose
 
Dominique Genet
No Relationships to Disclose
 
Nathalie Dohollou
No Relationships to Disclose
 
Isabelle Desmoulins
No Relationships to Disclose
 
Jean-Luc Re Canon
No Relationships to Disclose
 
Clara Guyonneau
No Relationships to Disclose
 
Adrien Buisson
No Relationships to Disclose
 
Louise-Marie Chevalier
Travel, Accommodations, Expenses - AstraZeneca
 
Suzette Delaloge
Consulting or Advisory Role - AstraZeneca (Inst); Besins Healthcare (Inst); Rappta Therapeutics (Inst); Sanofi (Inst); Sanofi (Inst)
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Exact Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis (Inst); Pfizer
 
Philippe Follana
Expert Testimony - AstraZeneca/MedImmune; Ipsen; Novartis; Tesaro
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Tesaro